Cannabinoids Guide

The primary psychoactive compound in cannabis. THC binds directly to CB1 receptors in the brain, producing euphoria, relaxation, altered perception, appetite stimulation, and pain modulation. It is the most abundant cannabinoid in most commercial cannabis strains and the compound responsible for the "high." Effects depend heavily on dose, terpene context, and individual biology. THC content in flower typically ranges from 15% to over 30%.

The second most abundant cannabinoid. CBD does not produce a high and works through indirect mechanisms — modulating receptor activity, inhibiting anandamide breakdown, and interacting with serotonin and vanilloid receptors. Associated with calm, body ease, and potential support for occasional stress and discomfort. CBD can moderate THC's intensity, which is why balanced-ratio products are popular. The only FDA-approved cannabinoid medication (Epidiolex) is CBD-based.

CBN forms when THC degrades through age, heat, and light exposure. It is mildly psychoactive — roughly one-quarter the potency of THC. CBN is most commonly associated with sedation and sleepiness, and it appears frequently in sleep-focused products. However, some researchers believe CBN's sedative reputation may come from its synergy with other compounds (particularly myrcene and THC) rather than CBN acting alone. Still, anecdotal reports from consumers are consistent enough that CBN products have become a popular nighttime choice.

Sometimes called the "mother cannabinoid" because CBGA (its acidic form) is the precursor from which all other cannabinoids are synthesized in the plant. CBG is non-psychoactive and typically appears in very small quantities (under 1%) in mature cannabis, though breeders have developed CBG-rich strains. Early research suggests CBG may interact with both CB1 and CB2 receptors and could have antibacterial and appetite-stimulating properties. CBG products are growing in popularity as a complement to THC and CBD.

THCA is the raw, acidic form of THC found in living and freshly harvested cannabis. It is non-psychoactive — it does not produce a high when consumed raw. THCA converts to THC through decarboxylation (heating), which is why smoking, vaping, or baking cannabis activates its psychoactive properties. Some consumers use raw cannabis (juicing, etc.) to get THCA's potential benefits without psychoactive effects. When you see a high THCA percentage on lab results for flower, multiply by 0.877 and add the Delta-9 THC percentage to get total potential THC.

The raw, acidic precursor to CBD. Like THCA, CBDA is found in unheated cannabis and converts to CBD through decarboxylation. Early research suggests CBDA may interact with serotonin receptors and could have its own set of properties distinct from CBD. The CBDA research is still in early stages, but it represents an interesting area of cannabis science.

A naturally occurring minor cannabinoid that is structurally similar to Delta-9 THC but with a double bond on the eighth carbon instead of the ninth. It produces milder psychoactive effects — often described as a gentler, more clear-headed experience with less anxiety potential. Delta-8 occurs naturally in very small quantities, so most commercial Delta-8 products are synthesized from hemp-derived CBD through chemical conversion. This manufacturing process has raised quality and safety concerns, and regulatory frameworks around Delta-8 vary by state.

A minor cannabinoid that is generating significant interest. At low doses, THCV may actually block CB1 receptors (opposite to THC), potentially suppressing appetite rather than stimulating it. At higher doses, it activates CB1 receptors and produces a clear-headed, energetic, shorter-duration high. THCV is most commonly found in African sativa landrace strains like Durban Poison. Some brands are now developing THCV-rich products marketed for daytime energy and focus.